John M. Maraganore's most recent trade in Kymera Therapeutics Inc was a trade of 16,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 25, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kymera Therapeutics Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2025 | 16,000 | 16,000 | - | - | Stock Option (Right to Buy) | |
| Rapport Therapeutics Inc. | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 21,850 | 21,850 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 33,662 | 33,662 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 16,000 | 16,000 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 23,114 | 23,114 | - | - | Stock Option (Right to Buy) | |
| ProKidney Corp - Ordinary ... | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2023 | 48,128 | 48,128 | - | - | Director stock option (right to buy) | |
| Kymera Therapeutics Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 16,532 | 16,532 | - | - | Stock Option (Right to Buy) | |
| Agios Pharmaceuticals Inc | John M. Maraganore | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 1,500 | 28,528 (0%) | 0% | 0 | Common stock | |
| Beam Therapeutics Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 10,391 | 10,391 | - | - | Stock Option (Right to Buy) | |
| ProKidney Corp - Ordinary ... | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2022 | 614,013 | 614,013 | - | - | Common Units in ProKidney LP | |
| ProKidney Corp - Ordinary ... | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2022 | 614,013 | 614,013 | - | - | Class B Ordinary Shares | |
| Agios Pharmaceuticals Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 29,307 | 29,307 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 4,975 | 4,975 | - | - | Restricted stock unit | |
| Agios Pharmaceuticals Inc | John M. Maraganore | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 30,028 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | John M. Maraganore | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 0 | - | - | Restricted stock unit | |
| Kymera Therapeutics Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2021 | 14,167 | 234,299 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 189.13 per share. | 21 Dec 2021 | 6,315 | 227,984 (0%) | 0% | 189.1 | 1,194,356 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 186.02 per share. | 21 Dec 2021 | 319 | 227,663 (0%) | 0% | 186.0 | 59,340 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 190.50 per share. | 21 Dec 2021 | 2 | 227,982 (0%) | 0% | 190.5 | 381 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2021 | 2,368 | 22,632 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 42.22 per share. | 10 Dec 2021 | 2,368 | 220,132 (0%) | 0% | 42.2 | 99,977 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2021 | 1,124 | 63,876 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.95 per share. | 10 Dec 2021 | 1,124 | 216,925 (0%) | 0% | 89.0 | 99,980 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 96.45 per share. | 10 Dec 2021 | 1,036 | 215,801 (0%) | 0% | 96.4 | 99,922 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2021 | 1,036 | 73,964 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2021 | 839 | 51,661 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 119.13 per share. | 10 Dec 2021 | 839 | 217,764 (0%) | 0% | 119.1 | 99,950 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2021 | 33,978 | 0 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.10 per share. | 12 Nov 2021 | 33,978 | 248,743 (0%) | 0% | 7.1 | 241,244 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 172.22 per share. | 12 Nov 2021 | 14,518 | 216,118 (0%) | 0% | 172.2 | 2,500,290 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 170.36 per share. | 12 Nov 2021 | 10,365 | 238,378 (0%) | 0% | 170.4 | 1,765,781 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 171.35 per share. | 12 Nov 2021 | 7,742 | 230,636 (0%) | 0% | 171.4 | 1,326,592 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 173.25 per share. | 12 Nov 2021 | 683 | 215,435 (0%) | 0% | 173.3 | 118,330 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 174.34 per share. | 12 Nov 2021 | 670 | 214,765 (0%) | 0% | 174.3 | 116,808 | Common Stock |
| Beam Therapeutics Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Nov 2021 | 13,133 | 13,133 | - | - | Stock Option (Right to Buy) | |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2021 | 33,979 | 33,978 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.10 per share. | 13 Aug 2021 | 33,979 | 248,744 (0%) | 0% | 7.1 | 241,251 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 199.92 per share. | 13 Aug 2021 | 23,336 | 218,807 (0%) | 0% | 199.9 | 4,665,333 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 198.93 per share. | 13 Aug 2021 | 4,160 | 242,143 (0%) | 0% | 198.9 | 827,549 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 200.84 per share. | 13 Aug 2021 | 3,828 | 214,979 (0%) | 0% | 200.8 | 768,816 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 198.02 per share. | 13 Aug 2021 | 2,441 | 246,303 (0%) | 0% | 198.0 | 483,367 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 201.55 per share. | 13 Aug 2021 | 214 | 214,765 (0%) | 0% | 201.6 | 43,132 | Common Stock |
| Agios Pharmaceuticals Inc | John M. Maraganore | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 28 May 2021 | 3,415 | 26,757 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | John M. Maraganore | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 1,686 | 28,443 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | John M. Maraganore | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 1,686 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 8,888 | 8,888 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 1,585 | 1,585 | - | - | Restricted stock unit | |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.10 per share. | 13 May 2021 | 33,979 | 248,744 (0%) | 0% | 7.1 | 241,251 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2021 | 33,979 | 67,957 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 131.18 per share. | 13 May 2021 | 11,203 | 220,893 (0%) | 0% | 131.2 | 1,469,610 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 130.34 per share. | 13 May 2021 | 9,121 | 232,096 (0%) | 0% | 130.3 | 1,188,831 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 129.32 per share. | 13 May 2021 | 4,512 | 241,217 (0%) | 0% | 129.3 | 583,492 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 132.32 per share. | 13 May 2021 | 3,481 | 217,412 (0%) | 0% | 132.3 | 460,606 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 128.30 per share. | 13 May 2021 | 3,015 | 245,729 (0%) | 0% | 128.3 | 386,825 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 133.56 per share. | 13 May 2021 | 1,624 | 215,788 (0%) | 0% | 133.6 | 216,901 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 134.37 per share. | 13 May 2021 | 1,023 | 214,765 (0%) | 0% | 134.4 | 137,461 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2021 | 16,236 | 222,272 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 131.75 per share. | 19 Apr 2021 | 7,237 | 215,035 (0%) | 0% | 131.8 | 953,475 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 134.62 per share. | 19 Apr 2021 | 270 | 214,765 (0%) | 0% | 134.6 | 36,347 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 79,998 | 79,998 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2021 | 33,979 | 101,936 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.10 per share. | 24 Feb 2021 | 33,979 | 240,015 (0%) | 0% | 7.1 | 241,251 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 146.13 per share. | 24 Feb 2021 | 9,376 | 223,509 (0%) | 0% | 146.1 | 1,370,115 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 145.15 per share. | 24 Feb 2021 | 6,129 | 232,885 (0%) | 0% | 145.1 | 889,624 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 146.98 per share. | 24 Feb 2021 | 6,097 | 217,412 (0%) | 0% | 147.0 | 896,137 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 148.00 per share. | 24 Feb 2021 | 4,375 | 213,037 (0%) | 0% | 148 | 647,500 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 150.22 per share. | 24 Feb 2021 | 2,054 | 209,619 (0%) | 0% | 150.2 | 308,552 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 151.31 per share. | 24 Feb 2021 | 1,415 | 208,204 (0%) | 0% | 151.3 | 214,104 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 148.96 per share. | 24 Feb 2021 | 1,364 | 211,673 (0%) | 0% | 149.0 | 203,181 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 152.46 per share. | 24 Feb 2021 | 1,138 | 207,066 (0%) | 0% | 152.5 | 173,499 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 143.88 per share. | 24 Feb 2021 | 1,001 | 239,014 (0%) | 0% | 143.9 | 144,024 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 154.59 per share. | 24 Feb 2021 | 599 | 206,036 (0%) | 0% | 154.6 | 92,599 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 153.33 per share. | 24 Feb 2021 | 431 | 206,635 (0%) | 0% | 153.3 | 66,085 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 17,504 | 52,500 | - | - | Performance Stock Option 2017 (right to buy) | |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 14,166 | 211,755 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.00 per share. | 11 Feb 2021 | 5,412 | 206,343 (0%) | 0% | 156 | 844,272 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 151.94 per share. | 11 Feb 2021 | 307 | 206,036 (0%) | 0% | 151.9 | 46,645 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Nov 2020 | 34,765 | 0 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.14 per share. | 19 Nov 2020 | 34,765 | 232,354 (0%) | 0% | 9.1 | 317,752 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 123.55 per share. | 19 Nov 2020 | 18,987 | 213,367 (0%) | 0% | 123.6 | 2,345,844 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 125.35 per share. | 19 Nov 2020 | 10,187 | 197,691 (0%) | 0% | 125.3 | 1,276,940 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 124.49 per share. | 19 Nov 2020 | 5,489 | 207,878 (0%) | 0% | 124.5 | 683,326 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 126.62 per share. | 19 Nov 2020 | 102 | 197,589 (0%) | 0% | 126.6 | 12,915 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2020 | 34,765 | 34,765 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.14 per share. | 20 Aug 2020 | 34,765 | 232,354 (0%) | 0% | 9.1 | 317,752 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 136.07 per share. | 20 Aug 2020 | 21,448 | 206,131 (0%) | 0% | 136.1 | 2,918,429 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 136.86 per share. | 20 Aug 2020 | 8,542 | 197,589 (0%) | 0% | 136.9 | 1,169,058 | Common Stock |
| Alnylam Pharmaceuticals Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 135.09 per share. | 20 Aug 2020 | 4,775 | 227,579 (0%) | 0% | 135.1 | 645,055 | Common Stock |